Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2012

01-08-2012 | Original Article

Evaluation of Early Atherosclerosis in Patients with Inflammatory Bowel Disease

Authors: Hasan Kayahan, Ismail Sari, Nesat Cullu, Fahize Yuksel, Serdal Demir, Mesut Akarsu, Yigit Goktay, Belkis Unsal, Hale Akpinar

Published in: Digestive Diseases and Sciences | Issue 8/2012

Login to get access

Abstract

Background

Data regarding early atherosclerosis and inflammatory bowel disease are limited and conflicting results are present.

Aims

The purpose of this study was to evaluate serological and sonographical evidence of subclinical vascular involvement in patients with inflammatory bowel disease.

Methods

Thirty-nine patients with inflammatory bowel disease (20 Crohn's disease, and 19 ulcerative colitis patients) and 31 healthy controls were consecutively enrolled in the study. Flow mediated dilatation of the brachial artery and intima media thickness assessments of the common carotid artery were measured sonographically. Soluble CD40 ligand levels were evaluated. Crohn's disease activity index and modified Truelove-Witt’s criteria were also noted.

Results

Age, sex distribution, serum lipids, smoking status, and intima media thickness of the common carotid artery were similar between the inflammatory bowel disease patients and controls (p > 0.05). However, both endothelium dependent and independent flow mediated dilatation values were significantly impaired in the inflammatory bowel disease group compared with healthy controls (p < 0.05). Erythrocyte sedimentation rate, C-reactive protein and soluble CD40 ligand values were significantly increased in inflammatory bowel disease patients compared with controls (p < 0.05), and soluble CD40 ligand was negatively correlated with flow mediated dilatation (r = −0.3, p < 0.05). Flow mediated dilatation was significantly predicted from the concentrations of C-reactive protein and soluble CD40 ligand.

Conclusion

Functional atherosclerosis is present in inflammatory bowel disease before early structural changes occur in vasculature. Higher sCD40L may indicate worse vascular outcome for IBD.
Literature
1.
go back to reference Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138.PubMedCrossRef Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138.PubMedCrossRef
2.
go back to reference Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.PubMedCrossRef Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.PubMedCrossRef
3.
4.
go back to reference Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med. 2004;9:46–54.PubMedCrossRef Poredos P. Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med. 2004;9:46–54.PubMedCrossRef
6.
go back to reference Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40:S253–S259.PubMedCrossRef Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40:S253–S259.PubMedCrossRef
7.
go back to reference Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741–747.PubMedCrossRef Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741–747.PubMedCrossRef
8.
go back to reference van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn’s disease. J Lipid Res. 2007;48:2640–2646.PubMedCrossRef van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn’s disease. J Lipid Res. 2007;48:2640–2646.PubMedCrossRef
9.
go back to reference Schinzari F, Armuzzi A, De Pascalis B, et al. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn’s disease. Clin Pharmacol Ther. 2008;83:70–76.PubMedCrossRef Schinzari F, Armuzzi A, De Pascalis B, et al. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn’s disease. Clin Pharmacol Ther. 2008;83:70–76.PubMedCrossRef
10.
go back to reference Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7:175–182.PubMedCrossRef Roifman I, Sun YC, Fedwick JP, et al. Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7:175–182.PubMedCrossRef
11.
go back to reference Papa A, Santoliquido A, Danese S, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:839–846.PubMedCrossRef Papa A, Santoliquido A, Danese S, et al. Increased carotid intima-media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:839–846.PubMedCrossRef
12.
go back to reference Kocaman O, Sahin T, Aygun C, Senturk O, Hulagu S. Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12:166–171.PubMedCrossRef Kocaman O, Sahin T, Aygun C, Senturk O, Hulagu S. Endothelial dysfunction in patients with ulcerative colitis. Inflamm Bowel Dis. 2006;12:166–171.PubMedCrossRef
13.
go back to reference Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis. 2011;5:41–47.PubMedCrossRef Haapamaki J, Roine RP, Turunen U, Farkkila MA, Arkkila PE. Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. J Crohns Colitis. 2011;5:41–47.PubMedCrossRef
14.
go back to reference Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology. 2010;61:198–204.PubMedCrossRef Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology. 2010;61:198–204.PubMedCrossRef
15.
go back to reference Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050–1055.PubMedCrossRef Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050–1055.PubMedCrossRef
16.
go back to reference Broide E, Schopan A, Zaretsky M, Kimchi NA, Shapiro M, Scapa E. Intima-media thickness of the common carotid artery is not significantly higher in Crohn’s disease patients compared to healthy population. Dig Dis Sci. 2011;56:197–202.PubMedCrossRef Broide E, Schopan A, Zaretsky M, Kimchi NA, Shapiro M, Scapa E. Intima-media thickness of the common carotid artery is not significantly higher in Crohn’s disease patients compared to healthy population. Dig Dis Sci. 2011;56:197–202.PubMedCrossRef
17.
go back to reference Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102:662–667.PubMedCrossRef Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102:662–667.PubMedCrossRef
18.
go back to reference Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.PubMedCrossRef Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845.PubMedCrossRef
19.
go back to reference Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610.PubMedCrossRef Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610.PubMedCrossRef
20.
go back to reference Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.PubMedCrossRef Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979.PubMedCrossRef
21.
go back to reference Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006;45:283–286.CrossRef Sari I, Okan T, Akar S, et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006;45:283–286.CrossRef
22.
go back to reference Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis. 2010;212:377–382.PubMedCrossRef Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis. 2010;212:377–382.PubMedCrossRef
23.
go back to reference Sherer Y, Zinger H, Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity. 2010;43:98–102. Sherer Y, Zinger H, Shoenfeld Y. Atherosclerosis in systemic lupus erythematosus. Autoimmunity. 2010;43:98–102.
24.
go back to reference Jackson LM, O’Gorman PJ, O’Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM Mon J Assoc Phys. 1997;90:183–188. Jackson LM, O’Gorman PJ, O’Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM Mon J Assoc Phys. 1997;90:183–188.
25.
go back to reference Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247–251.PubMedCrossRef Webberley MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247–251.PubMedCrossRef
26.
go back to reference Scaldaferri F, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol. 2011;17:594–608.PubMedCrossRef Scaldaferri F, Lancellotti S, Pizzoferrato M, De Cristofaro R. Haemostatic system in inflammatory bowel diseases: new players in gut inflammation. World J Gastroenterol. 2011;17:594–608.PubMedCrossRef
27.
go back to reference Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896–899.PubMedCrossRef Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896–899.PubMedCrossRef
28.
go back to reference Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007;17:118–123.PubMedCrossRef Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007;17:118–123.PubMedCrossRef
29.
go back to reference Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother. 2004;38:1500–1508.PubMedCrossRef Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother. 2004;38:1500–1508.PubMedCrossRef
30.
go back to reference Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435–1441.PubMedCrossRef Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52:1435–1441.PubMedCrossRef
31.
go back to reference Koutroubakis IE, Theodoropoulou A, Xidakis C, et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:1147–1152.PubMedCrossRef Koutroubakis IE, Theodoropoulou A, Xidakis C, et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2004;16:1147–1152.PubMedCrossRef
Metadata
Title
Evaluation of Early Atherosclerosis in Patients with Inflammatory Bowel Disease
Authors
Hasan Kayahan
Ismail Sari
Nesat Cullu
Fahize Yuksel
Serdal Demir
Mesut Akarsu
Yigit Goktay
Belkis Unsal
Hale Akpinar
Publication date
01-08-2012
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2012
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-012-2148-x

Other articles of this Issue 8/2012

Digestive Diseases and Sciences 8/2012 Go to the issue